Pharmaceuticals, Biotechnology and Life Sciences
Findings from Pooled Analysis of KEYNOTE-189, KEYNOTE-407 and KEYNOTE-021 (Cohort G) Presented at the IASLC 2019 World Conference on Lung…
Cannabinoids bind to A3AR, the target of Can-Fite’s drugs Can-Fite’s unparalleled expertise in these targets will be utilized to develop…
Joint venture brings together AI technology and living tumor organoids to develop novel personalized therapies for cancer patients SEATTLE, Wash.…
SAN FRANCISCO & CLEVELAND–(BUSINESS WIRE)–Atomwise, Inc. the leader in artificial intelligence (AI) for drug discovery, announced today the launch of…
DUBLIN–(BUSINESS WIRE)–The “Specialty Pharmaceuticals Market, by Country (US, UK, France, Germany, Italy, Spain, Japan, South Korea), Application, Company, Global Analysis”…
—Jean-Marc Renard, MS, MBA, joins as Chief Business Officer — —Emmanuel Prestat, PhD, joins as Computational Biology Manager — LYON,…
Alliance will support the clinical progression of Celyad’s non-gene edited allogeneic CAR-T candidates MINNEAPOLIS & MONT-SAINT GUIBERT, Belgium–(BUSINESS WIRE)–Be The…
@Boehringer has the first FDA-approved therapy to slow the rate of decline in pulmonary function for systemic sclerosis-associated interstitial lung disease
Additionally, Pfizer Has Completed Enrollment of its Phase 3 Studies (NCT03828617, NCT03835975 and NCT03760146) for its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
Allergan and Molecular Partners’s Abicipar pegol DARPin therapy was accepted by FDA in the USA, and the European Medicines Agency (EMA) has validated a Marketing Authorisation Application (MAA), for patients with neovascular (wet) age-related macular degeneration (nAMD).